gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Serine/threonine kinase 33

Top mentioned proteins: KRAS, fibrillin-1, CAN, vimentin, HAD
Papers on STK33
STK33 promotes hepatocellular carcinoma through binding to c-Myc.
Shen et al., Shanghai, China. In Gut, Jan 2016
OBJECTIVE: STK33 has been reported to play an important role in cancer cell proliferation.
Virus-encoded microRNA contributes to the molecular profile of EBV-positive burkitt lymphomas.
Leoncini et al., Bologna, Italy. In Oncotarget, Aug 2015
Among others, we identified LIN28B, CGNL1, GCET2, MRAS, PLCD4, SEL1L, SXX1, and the tyrosine kinases encoding STK10/STK33, all provided with potential pathogenetic significance.
STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential.
Zhang et al., Kunming, China. In Acta Biochim Biophys Sin (shanghai), Mar 2015
Serine/threonine kinase 33 (STK33) is a novel protein that has attracted considerable interest in recent years.
STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis.
Li et al., Jinan, China. In Bmc Cancer, 2014
BACKGROUND: The role of serine/threonine kinase 33 (STK33) gene in tumorigenesis is still controversial.
The serine/threonine kinase 33 is present and expressed in palaeognath birds but has become a unitary pseudogene in neognaths about 100 million years ago.
Schmidt et al., Mainz, Germany. In Bmc Genomics, 2014
BACKGROUND: Serine/threonine kinase 33 (STK33) has been shown to be conserved across all major vertebrate classes including reptiles, mammals, amphibians and fish, suggesting its importance within vertebrates.
Exploring genetic markers of adult obesity risk in black adolescent South Africans-the Birth to Twenty Cohort.
Lombard et al., Johannesburg, South Africa. In Nutr Diabetes, 2014
The SNPs were in or near GNPDA2 (rs10938397), MTCH2 (rs10838738), NEGR1 (rs2568958), SH2B1 (rs7498665), STK33 (rs10769908) and TMEM18 (rs6548238).
Co-localization of serine/threonine kinase 33 (Stk33) and vimentin in the hypothalamus.
Schmidt et al., Mainz, Germany. In Cell Tissue Res, 2014
We investigate the immunoreactivity of serine/threonine kinase 33 (Stk33) and of vimentin in the brain of mouse, rat and hamster.
Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer.
Park et al., Seoul, South Korea. In J Exp Clin Cancer Res, 2013
The mRNA expression of AKR1B1, CHST10, ELOVL4, FLI1, SOX5, STK33, and ZNF304 was restored by treatment with 5-aza-dC and vincristine.
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.
Munoz et al., Cambridge, United States. In Acs Med Chem Lett, 2013
In 2009, RNAi experiments revealed that lowering mRNA levels of a transcript encoding the serine/threonine kinase STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers.
The STK33-linked SNP rs4929949 is associated with obesity and BMI in two independent cohorts of Swedish and Greek children.
Schiöth et al., Uppsala, Sweden. In Plos One, 2012
closely associated with serine/threonine kinase 33 (STK33), to be associated with body mass.
NUDT3 rs206936 is associated with body mass index in obese Japanese women.
Hotta et al., Kyoto, Japan. In Endocr J, 2012
We measured the VFA and SFA of 1424 obese Japanese subjects (BMI ≥ 25 kg/m(2), 635 men and 789 women) who were genotyped for 13 single nucleotide polymorphisms (SNPs) reported by recent GWASs, namely, TNNI3K rs1514175, PTBP2 rs1555543, ADCY3 rs713586, IRS1 rs2943650, POC5 rs2112347, NUDT3 rs206936, LINGO2 rs10968576, STK33 rs4929949, MTIF3 rs4771122, SPRY2 rs534870, MAP2K5 rs2241423, QPCTL rs2287019, and ZC3H4 rs3810291.
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
Scholl et al., Ulm, Germany. In J Exp Med, 2012
Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target.
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Golub et al., Cambridge, United States. In Proc Natl Acad Sci U S A, 2012
Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent cancer cells were proposed to have a unique requirement for the serine/threonine kinase STK33.
Screen for Inhibitors of STK33 Kinase Activity
Schreiber et al., Bethesda, United States. In Unknown Journal, 2012
In 2009, Serine/threonine-protein kinase 33 (STK33) was identified as a synthetic lethal gene in KRAS-dependent cell lines through Ribonucleic Acid Interference (RNAi) experiments.
STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Dussault et al., Thousand Oaks, United States. In Cancer Res, 2011
STK33 downregulation or dominant mutant overexpression had no effect on KRAS signaling or survival of cancer cells.
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Gilliland et al., Boston, United States. In Cell, 2009
STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells.
Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men.
Schmidt et al., Mainz, Germany. In Febs J, 2005
STK33/Stk33 expression pattern resembles those of some related members of the calcium/calmodulin dependent kinase group
share on facebooktweetadd +1mail to friends